Phenominer Database Results (12 results)

 

Table "column sort" updates the order of the bars in the chart.
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Time Value Method Notes Clinical Measurement Notes Record ID Study ID
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-163 days 18 89.0 % necropsy 0.0 0 two treatment fluorouracil 5-FU 111155 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-157 days 15 53.0 % necropsy 0.0 0 one treatment 5-fluorouracil + interleukin-2 111136 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-147 days 14 100.0 % necropsy 0.0 0 one treatment thymosin alpha-1 + interleukin-2 111138 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-162 days 15 13.0 % necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 +interleukin-2 111139 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-142 days 13 100.0 % necropsy 0.0 0 saline control group 111132 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-146 days 15 93.0 % necropsy 0.0 0 one treatment fluorouracil 5-FU 111133 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-146 days 15 93.0 % necropsy 0.0 0 one treatment interleukin-2 111135 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-186 days 21 9.5 % necropsy 0.0 0 two treatments 5-fluorouracil + thymosin alpha-1 +interleukin-2 111157 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-141 days 14 100.0 % necropsy 0.0 0 one treatment thymosin alpha-1 111134 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-145 days 15 87.0 % necropsy 0.0 0 one treatment 5-fluorouracil + thymosin alpha-1 111137 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) and splenectomy then 0.9% sodium chloride solution (2 ml) (for 7 days) then 0.9% sodium chloride solution (2 ml) (for 7 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-144 days 16 100.0 % necropsy 0.0 0 two treatment regimen saline control group 111154 3196
BDIX/OrlCrl percentage of study population developing extra-hepatic metastases during a period of time DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. peritoneum integrity trait male 77 days-164 days 18 22.0 % necropsy 0.0 0 two treatments 5-fluorouracil + interleukin-2 111156 3196